Christopher Anzalone

President, Chief Executive Officer, and Director at ARROWHEAD PHARMACEUTICALS

Board

Since December 1, 2007

Age

55 years

Education

Earned a Ph.D. in Biology from UCLA and a B.A. in Government from Lawrence University.

Tenure

Joined ARWR on December 1, 2007 and has served as President, Chief Executive Officer, and Director since then.

Also at ARROWHEAD PHARMACEUTICALS

James Hamilton

Chief of Discovery and Translational Medicine

KAM

Kenneth A. Myszkowski

Chief Financial Officer

PCO

Patrick C. OBrien

Chief Operating Officer and General Counsel

About

Christopher Anzalone is 55 years old and has built a career marked by significant accomplishments in biotechnology leadership. He earned his Ph.D. in Biology from UCLA and his B.A. in Government from Lawrence University, establishing a strong academic foundation for his future endeavors.

Since December 1, 2007, he has served as President, Chief Executive Officer, and Director at ARWR, guiding the company through various phases of business and technical development. His leadership has been instrumental in shaping strategic partnerships and advancing the company's innovative pipeline in the biotechnology sector.

Prior to his tenure at ARWR, he held key roles in the private equity and biotechnology fields, including founding the Benet Group LLC and serving as a partner at Galway Partners, LLC. His diverse professional background underscores a deep commitment to fostering innovation and driving business growth within the sector.

$ARWR Performance Under Christopher Anzalone

Past Roles

Organization	Role	Date Range	Details
The Benet Group LLC	Founder and Chief Executive Officer	Prior to December 1, 2007	A private equity firm focused on creating and building new nano-biotechnology companies from university-generated science
Galway Partners, LLC	Partner	1999 to 2003	A Washington, DC-based private equity firm involved in sourcing, structuring, and building new business ventures

Fixed Compensation

Data from FY 2024

Component Name	Amount	Payment Schedule	Additional Details
Salary	$951,012	N/A	Fiscal year 2024
Non-Equity Incentive Plan Compensation	$1,152,000	N/A	Fiscal year 2024
All Other Compensation	$1,461	N/A	Includes 401(k) matching contributions and life insurance premiums

Performance Compensation

Data from FY 2024

Grant Details

Metric	Value	Additional Details
Grant Date	December 22, 2023	N/A
Grant Type	Performance-based Restricted Stock Units (PRSUs)	N/A
Grant Date Fair Value	$10,319,000	N/A
Number of Shares Granted	340,000 PRSUs	N/A

Vesting and Performance

Metric	Value	Additional Details
Vesting Condition	Specific performance condition	Determined to be 100% probable as of the grant date
Vesting Schedule	Not explicitly detailed	N/A
Performance Metrics	Not provided	Detailed thresholds, targets, weights not provided